Introduction
.
PMP22 is a small, integral membrane protein exMyelin formation by glial cells and its maintenance in pressed mainly by myelin-forming Schwann cells (Snipes the adult nervous system requires the coordinated exet al., 1992) . With four predicted transmembrane dopression of a group of membrane-associated proteins mains, PMP22 belongs to a diverse group of four-helix that become major structural components of the myelin bundle proteins localized in myelin (Snipes and Suter, sheath (for review, see Lemke, 1988; Hudson, 1990; 1995b) . Although PMP22 was identified as a peripheral Nave, 1995; Snipes and Suter, 1995a) . The function of myelin protein that is downregulated in Schwann cells these proteins for the architecture of compacted myelin after injury-induced denervation (Kitamura et al., 1976 ; has been studied intensively with the help of naturally Spreyer et al., 1991; Welcher et al., 1991) , PMP22 exoccurring and artificially generated mutants.
pression is not specific to PNS myelin. In fact, PMP22 In humans, the genetically determined failure to asis the rat homolog of gas3, one of several growth arrestspecific genes of unknown function, originally cloned semble or maintain PNS myelin defines a heterogeneous The exact location of exons 3 and 4 has not been determined; the position of a genomic fragment (5Ј probe) used for library screening and Southern blot analysis is indicated. Shown below is the exon-intron organization ofPMP22 (intron sizes not to scale) with the approximate position of primers used for RT-PCR (primer pair AB) and genotyping (primer pair CD). Most PMP22 transcripts in Schwann cells contain exon 1A . Indicated are restriction sites NruI (Nr), KpnI (K), BamHI (B), SalI (S), PstI (P; in mouse only), and NotI (N; in rat only). (B) Routine identification oftransgenicrats utilizes mouse-specific PCR primers from exon 5. Shown is a genotype analysis from a representative F1 litter. Presence of a 501 bp PCR product correlates with a visible phenotype (ϩ) at 2.5 months of age. (C) Southern blot analysis of PMP22-transgenic rats (tg1, tg2 from B; tg5) and a nontransgenic littermate (wt1 from (B) using the mouse-specific 5Ј probe. In BamHI-digested rat DNA (10 g) of tail biopsies, a 2.3 kb fragment is specific for the murine PMP22 transgene, as confirmed by the presence of the same fragment in normal mouse genomic DNA (lane M, 15 g). A homozygous rat in the F2 generation (hz1) has twice the transgene dosage of a heterozygous littermate (tg5), when normalized to the signal of an internal control gene (data not shown).
from murine NIH 3T3 cells (Schneider et al., 1988; Manfi- of exon 5 ( Figure 1A ). DNA-microinjection of fertilized Sprague-Dawley rat oocytes resulted in the generation oletti et al., 1990) . PMP22gene transcripts have also been detected in spinal cord motorneurons and in several of one founder male that was able to breed normally and was used to set up a line of PMP22-transgenic rats. embryonic and adult tissues outside the nervous system (Baechner et al., 1995; Parmantier et al., 1995) . The norTo estimate the transgene copy number, we compared by Southern blot analysis genomic DNA from mal function of PMP22 is not known. In mutant mice that completely lack PMP22 expression, PNS myelination transgenic rats with a series of mouse genomic standards, utilizing a mouse-specific probe of the PMP22 is delayed and followed by focal hypermyelination and myelin degeneration (Adlkofer et al., 1995) . Taken togene (data not shown). Based on the phosphoimager analysis of hybridization signals, we estimated that three gether, the available genetic data have demonstrated that PMP22 is required for normal Schwann cell differencopies of the microinjected DNA fragment constitute the PMP22 transgene. For all subsequent genotype detiation and overall myelin stability. Although PMP22 is expressed outside the nervous system, the reported terminations, we employed a PCR-based assay, and the amplification of a 501 bp genomic fragment with mouseabnormalities in the known PMP22 mutants are restricted to Schwann cells specific primers ( Figures 1B and 1C ). To investigate whether dosage increase is sufficient to turn the wild-type PMP22 gene into a disease gene, Peripheral Neuropathy in we have generated a transgenic rodent model. Here we PMP22-Transgenic Rats show by a combination of genetic, behavioral, morphoAt about 2 months of age, the founder male displayed logical, and electrophysiological criteria that PMP22-an unsteadiness of gait, reminiscent of the 'steppage' overexpressing rats develop a peripheral neuropathy gait in CMT patients. Tremor or seizures were absent. In that closely mimics autosomal-dominant CMT1A. The the progeny, 43 of 86 animals showed a similar unsteady CMT-rat serves as a novel tool to investigate the behavgait, correlating with a presence ofthe PMP22 transgene. ior of PMP22 overexpressing Schwann cells in vivo and A loss of muscle strength became obvious when rats in vitro.
tried to right up at the cage wall ( Figure 2A ). When walking over a flat surface in a straight line, transgenic rats Results moved clumsily and most displayed a notable outward positioning of their hind feet ( Figure 2B ). Despite some interindividual variations in phenotype, Generation of PMP22-Transgenic Rats We attempted to increase the PMP22 gene dosage in transgenic rats (n ϭ 23) failed uniformly in a simple behavioral assay of motor performance and grip the rat that is the preferred model system for studying Schwann cell development in vivo and in vitro. The wildstrength, the bar test ( Figure 3A) . When placed on a round horizontal bar (diameter 1.5 cm), wild-type rats type gene was cloned from a 129SV mouse cosmid genomic library. A 43 kb restriction fragment that conlearned, within a set of six trials, to balance and support their weight. In contrast, transgenic rats were unable to tained the PMP22 transcription unit was excised, including 7 kb upstream of exon 1A and 4 kb downstream stay on the bar and dropped within the first minute. While this test served as a reliable indicator of transgenicity for axonal degeneration in PMP22-transgenic rats (see beyounger rats, older animals had also difficulties because low), EMG recordings from the plantar foot muscles of their increased body weight. To measure the motor disclosed moderate to abundant fibrillation potentials performance of 11 month-old rats, we chose the rotarod and positive sharp waves ( Figure 4B ), suggesting a partest for moving animals. Rats (n ϭ 9) were placed on tial muscle denervation. a 10 cm wide, horizontal rod (diameter 10 cm), with shieldings on each side. After 30 s at rest, the rod was Peripheral Hypomyelination of rotated slowly at one round per min, and this speed was PMP22-Transgenic Rats doubled every minute ( Figure 3B ). The average time that A morphological analysis demonstrated the loss of myrats were able to stay on the rod differed significantly elin in peripheral and cranial nerves. In cross sections between PMP22-transgenic rats and age-matched wildof sciatic nerves, many axons had thin or absent myelin type rats, also demonstrating a deficit of motor perforsheaths ( Figures 5A-5C and 6A). The extent of hypomymance in older animals.
elination differed between individuals and correlated with the visible phenotype. At 2.5 months of age, very occasional supernumerary Schwann cell processes and Reduced Nerve Conduction Velocity basal laminae surrounded hypomyelinated or amyelinThe hallmark of CMT1 is the reduction of nerve-conducated axons (early onion bulbs) ( Figure 6A ). By 6 months tion velocities (NCV) in peripheral nerves. PMP22-transof age, onion bulbs were extensive (Figures 5A, 6B, and genic rats were analyzed at 2.5 months of age and 6C). The severity of abnormalities was greater in the showed a substantial decrease of the conductive propventral nerve roots compared with dorsal roots (Figures erties of both motor and sensory nerves ( Figure 4A ; 5E and 5F) or the distal sciatic and tibial nerves. The Table 1 ). Compound motor action potential (CMAP) laventral/dorsal difference was still reflected in the periphtencies were increased, resulting in a motor nerve conery, as nerves that are predominantly motor (e.g., branch duction velocity of 14.7 (Ϯ 5.1) m/s in transgenic rats, to medial gastrocnemius) were more severely affected compared with 36.4 (Ϯ 2.5) m/s in wild-type littermates.
than those that are predominantly sensory (e.g., distal Increases in latency were also found for minor distibial nerves; data not shown). charges of antidromically activated motorneurons
In general, hypomyelination was more marked in (F-waves). In addition to slowing of the NCV, CMAP larger diameter fibers (presumably motor), while many amplitude from distal stimulation were reduced. Sensory smaller fibers had sheaths of normal or even increased nerve action potentials (SNAPs) could be recorded in thickness (Figures 5C and 6B) . The myelin deficit was two rats, and NCV was reduced to 14.9 (Ϯ 7.2) m/s in variable along individual fibers (segmental demyelintransgenics from 34.5 (Ϯ 4.0) m/s in the wild type (Table  ation) , even within a single internode ( Figure 5G ). Myelin 1). Thus, reductions of NCV were similar to the findings sheaths were well compacted with normal periodicity. in patients with CMT1A (Kaku et al., 1993) . Recordings
Myelin debris was seen only occasionally in Schwann made at a distance of 40 mm from the stimulating eleccells, and reactive macrophages were not a feature. The trode showed characteristic desynchronization of amount of endoneurial collagen was increased. Axonal CMAP (polyphasia) in transgenic rats, which represent degeneration was a rare finding involving less than 1% physiological signs of demyelination ( Figure 4A ). Although there was minimal morphological evidence of of fibers. Neuronal cell bodies in the dorsal root ganglia Electrophysiological recordings are from 2.5 month-old heterozygous transgenic rats and agematched nontransgenic controls. All data are expressed as mean Ϯ SD. Sample size is n ϭ 5 (PMP22-transgenics) and n ϭ 3 (age-matched controls), except where indicated. All differences between wild type and transgenics are significant ( a p Ͻ 0.01; b p Ͻ 0.021; by two-tailed Mann-Whitney-U test).
and ventral horn were unremarkable and no abnormalities were detected in CNS fibers (data not shown). Taken together, the morphological abnormalities of PMP22-transgenic rats closely resemble the pathology of human (A) In the bar test, the time (in seconds Ϯ SEM) was recorded, in which 2.5 month-old heterozygous rats were able to stay on a 50
Homozygous PMP22-Transgenic Rats cm long rod (diameter 1.5 cm). In six consecutive trials, wild-type
Remain Amyelinated
rats (n ϭ 8) learned to balance, whereas PMP22-transgenic rats Homozygote PMP22-transgenic rats displayed a more (n ϭ 13) showed significant deficits. Maximal trial length was 300
severe and uniform phenotype. They never developed s. Differences are significant from the fourth trial on (p < 0.0025; a coordinated gait and were paralyzed at 4 weeks of Student's t-test).
(B) A rotarod test demonstrates motor deficits of older rats (11 age ( Figure 2C ). Occasionally, spasticity and seizures months). In a series of 6 consecutive trials, the cumulative time (in were observed. Symptoms were progressive and the seconds Ϯ SEM) was scored in which animals were able to stay on animals became severely retarded in development.
a slowly rotating roller (diameter 10 cm). After 30 s at rest, rotating
Many homozygotes died before 1 month of age or had speed (starting at 1 rpm) was increased in 60 s intervals to 2, 4, 8, to be sacrificed.
12, 16, and 20 rpm (indicated on the right). None of the PMP22-By light and electron microscopic analysis, homozytransgenic rats (n ϭ 6) was able to stay at 12 rpm (age-matched wild-type rats 20 rpm; n ϭ 3). Hold time was significantly lower in gous rats were completely lacking PNS myelin. Schwann transgenic animals (p < 0.05; Mann-Whitney-U-test) in all trials excells, which were increased in number, had segregated cept trial 3 (p < 0.071).
with axons in a normal 1:1 ratio and formed a basal lamina, but failed to assemble myelin (Figures 5D and recorded from a foot muscle after proximal and distal stimulation. Compared to 2.5 month-old wild-type rats (left), age-matched PMP22-transgenics show significantly increased latencies (right). Note the different horizontal and vertical calibration in the top panels. Drop in amplitude and marked temporal desynchronisation suggest hypomyelination. Numeric data are summarized in Table 1 . The reduction of NCV closely resembles recordings in human patients with CMT1A.
(B) Representative EMG traces from a foot muscle of wild-type (left) and PMP22-transgenic rats (right). Note the absence of spontaneous electrical activity in normally innervated muscle of the wild type, and the spontaneous activity in PMP22-transgenic rats. The latter serves as an indirect but sensitive indicator of muscle fiber denervation. 6D). Many Schwann cells contained small membranous rats, in agreement with data from human biopsy material (Hanemann et al., 1994; Yoshikawa et al., 1994) . When collections ( Figure 6D ), though overt myelin debris was not seen. Supernumerary Schwann cells and onion the mean of the wild-type level (n ϭ 8) was defined as 1.0 (range 0.4-1.7), overexpression in age-matched bulbs were not present at 5 weeks of age. Endoneurial collagen was markedly increased (Figures 5D and 6D) transgenic rats (n ϭ 10) ranged from 1 to 4-fold ( Figure  7D ). Homozygotes at the age of 4 weeks showed up to and fibroblasts frequently contained lipid droplets. No abnormalities were detected in CNS fibers or unmyelin-6-fold elevated mRNA levels. When P0 mRNA was used as an internal standard, PMP22 mRNA levels were inated fibers of the PNS.
creased to the same extent. Interestingly, the degree of overexpression correlated with the severity of the visual Transcriptional PMP22 Overexpression CMT rats and their wild-type littermates were compared phenotype ( Figure 7D ). We specifically noted that two transgenic rats with the lowest PMP22 mRNA level were at both the RNA and protein levels. We used RT-PCR to quantitate PMP22 mRNA in the sciatic nerve, and not visibly affected (but they failed in the bar test). Transcriptional overexpression was also confirmed by PstI normalized results to GAPDH mRNA ( Figure 7A ) or to myelin protein zero (P0) mRNA ( Figure 7B ). Within the and NotI restriction digests, which separated transgenic (mouse) and endogenous (rat) PMP22 cDNA ( Figure 7B ). linear range of these reactions, amplification results were reproducable with a sample to sample deviation of <10% (data not shown).
Analysis of Myelin Proteins
Western blots revealed a slight decrease of PMP22 In the analysis of 18 animals (aged 2.5 months), we noted a considerable variation in the steady-state level protein in sciatic nerve extracts from 2.5 month-old transgenic rats (Figure 8) . A similar reduction was seen of PMP22 mRNA among transgenic and nontransgenic for the myelin proteins P0 and MBP, suggesting that a morpholgy was normal (data not shown). Thus, PMP22-transgenic Schwann cells showed no signs of premature deficit of these proteins reflects the hypomyelination by the time of analysis. When the same Western blot was growth arrest (as defined by exiting the cell cycle), and no evidence of increased apoptotic death, indicating reprobed with an antibody against ␤-actin, a higher steady-state level was detected in transgenic nerves, that the CMT1A disease mechanism is more complex than a dysregulation of Schwann cell growth. indicating a corresponding overrepresentation of axonderived proteins.
Discussion Normal Growth of Purified Schwann Cells in Culture
CMT is one of the most frequent human genetic diseases, and the autosomal-dominant subtype CMT1A is Rat Schwann cells that overexpress PMP22 cDNA in vitro show impaired growth kinetics (Zoidl et al., 1995) the most prevalent form. It has been suggested that CMT1A is caused by overexpression of one or more and high level PMP22 overexpression induces apoptosis of NIH3T3 cells (Fabretti et al., 1995) . We used our CMTdisease genes located in a segmentally duplicated region of 17p11.2 ; Raeymakers et al., rat model, to determine whether a disease-relevant increase of the PMP22 gene dosage is sufficient to alter 1991). We have proven this hypothesis directly by generating transgenic rats that overexpress the wild-type Schwann cell growth in vitro. Schwann cells were purified from 3 day-old rats and their growth was monitored PMP22 gene. PMP22-transgenic rats develop a peripheral neuropathy that closely resembles CMT1A by morin a double-blinded study (with respect to the presence of the PMP22 transgene). Absolute cell counts of 4 dayphological and physiological criteria. Although we have obtained only one line of transgenic old cultures, prepared from individual transgenic rats (n ϭ 6) and nontransgenic controls (n ϭ 11), showed no rats, we believe that the hypomyelinated phenotype is a true model of human CMT1A. A random integration significant difference (Figure 9) . Also, the number of DNA synthesizing Schwann cells, nearly 100% as visualized artifact is unlikely to result in an autosomal-dominant model of CMT. Moreover, high-level overexpression of by the incorporation of BrdU, was not reduced and the Figure 7 . Elevated PMP22 mRNA Levels in Sciatic Nerves of Transgenic Rats (A) Quantitative RT-PCR and phosphoimage analysis was used to compare the steadystate levels of PMP22 mRNA, relative with GAPDH mRNA in a 2.5 month-old PMP22-transgenic rat (right) and age-matched wild type (left). Within the linear range of this assay, the PMP22-specific PCR product (636 bp) is more abundant in transgenics than in controls. GAPDH mRNA is unchanged. (B) The amplified PMP22 cDNA (636 bp) was digested with PstI and NotI, resulting in mousespecific fragments (570 bp and 66 bp; transgene-derived) and rat-specific fragments (480 bp and 156 bp). Shown are the 570 bp and 480 bp fragments separated on a 5% acrylamide gel. Lanes 1, wild type (4 weeks of age); 2, wild type (2.5 months); 3 and 4, heterozygous (2.5 months); 5 and 6, homozygous (4 weeks). Note that PMP22 expression is higher in 4 week-old rats. Amplification products are from PCR cycle 21. 5 months) ; open squares, homozygous transgenics (4 weeks). Phosphoimager readings were normalized to the average PMP22 mRNA level in the nontransgenic group (defined as 1.0) and using GAPDH mRNA as an internal standard. The visible phenotype of PMP22-transgenic rats is indicated on the right and ranked as: -(not obvious; bar test average <100 s), ϩ (unsteady gate; bar test average < 60 s), ϩϩ (more severe, bar test average <20 s), and ϩϩϩϩ (paraplegic). Bar test average of wild-type rats was 120 s (average hold time over six trials). Note that PMP22 overexpression levels correlate with differences in visible phenotype. Overexpression of transgenic rats is significant (p<0.005; 2-tailed Mann-Whitney-UTest).
PMP22 in three independent lines of mice caused a the wild-type, closely resembling the changes found in patients with CMT1 (Dyck et al., 1993; Kaku et al., 1993) . congenital dysmyelination similar in phenotype to the homozygous PMP22-transgenic rats described in this There was also marked temporal dispersion of the evoked CMAPs, a feature typical of peripheral demyelinreport (Magyar et al., unpublished data) .
The electrophysiological hallmark of human CMT1 is ation in CMT1A. The degree of changes was rather homogenous in a given animal, but showed interindividual the reduction of conductive properties of motor and sensory nerves. In our rat model, the mean nerve convariations similar to the findings in human patients. The CMT rat allows a detailed histological analysis duction velocities were decreased to half the values of integrity of myelin, suggesting that myelin-forming glial cells are particularly sensitive to the overexpression of their membrane protein genes. In this respect, we note that the PMP22 gene is not Schwann cell-specific, but also expressed in CNS motoneurons and a number of tissues outside the nervous system (Parmantier et al., 1995; Baechner et al., 1995) . Nevertheless, primary pathological changes in CMT1A patients and in this rodent model appear to be restricted to peripheral myelin.
Whereas patients with a duplication of the X-linked PLP gene have a similar clinical phenotype (Nave and Boespflug, 1996) , CMT1A patients with a duplication of 17p11.2 can differ significantly in clinical severity, suggesting an effect of modifier genes. However, clinical heterogeneity of CMT1A was even reported in two pairs of identical twins (Garcia et al., 1996) . The appearance of our PMP22-transgenic rats was likewise not uniform, although any combination of modifier genes should be identical. The CMT-rat model may help to identify epigenetic factors that contribute to the clinical variability and that could potentially lead to the development of preventive measures.
Point mutations altering the primary structure of three different membrane proteins, PMP22, P0, and connexin-32, have been associated with CMT1 (Hayasaka et al., 1993; Roa et al., 1993a; Bergoffen et al., 1993) , suggesting that mutant gene products and overexpression of wild-type PMP22 share an abnormal gain-of-function effect. However, the cellular disease mechanism remains obscure, and it is unknown why only Schwann phenotype of the rat is a complex mixture of a dysmyelination and a superimposed progressive demyelination. The same may be true for human patients with CMT1A, that is impossible in human patients. We observed the where a developmental analysis of biopsy material is classical features of CMT1, a segmental demyelination difficult and usually limited to a small segment of the associated with Schwann cell hypertrophy and onion (sensory) sural nerve. To better define the early onset bulb formation. These abnormalities were more prochanges, a detailed morphological analysis of multiple nounced in the ventral roots than in the dorsal roots, developmental time points will be required. which could explain why motor functions are generally
In homozygous PMP22-transgenic rats, spasticity and more impaired than sensory functions in patients with hind limb paralysis are lethal at about 4-6 weeks of CMT1A. In younger rats, we also found signs of dysmyeage (the cause of death may be indirect). At this stage, lination, which suggests that PMP22 overexpression has Schwann cells have segregated with axons in a 1:1 ratio features of both a developmental and a degenerative but have failed to myelinate. Some cells may continue disease.
to divide as precursor cells, causing the visible Schwann The myelin defect of PMP22-transgenic rats is remicell hypertrophy (data not shown). Although abnormal niscent of a transgenic mouse model of Pelizaeus-Merzcell death may occur in the context of this hypertrophy, bacher disease, in which dys-and demyelination of the we have no morphological evidence of apoptosis in CNS follow overexpression of the myelin proteolipid PMP22-transgenic rats at the ages studied. (PLP) gene (Readhead et al., 1994; Kagawa et al., 1994) .
Schwann cells appear sensitive to both increase and Thus, the CMT rat provides another example that indecrease of PMP22 expression levels. The loss of one creased dosage turns a normal gene into a disease gene.
PMP22 gene copy is linked to the hereditary neuropathy, with liability to pressure palsies (HNPP; Chance et al., Remarkably, both examples are diseases that affect the using a phosphorimager (Fuji BAS 1000). In these experiments, the 1993), a condition of myelin instability that can be modneuron-specific enolase gene served as an internal genomic stanelled in mice (Adlkofer et al., 1995) . The complete abdard, as described (Readhead et al., 1994). sence of PMP22 expression (that has not yet been described in the human) is associated with a severe myelin Behavioral Analysis defect in knock-out mice, caused by focal hypermyelinaAll experiments were conducted before the rats were genotyped. tion and subsequent degeneration of myelin sheaths
In the standardized bar test, a round metal bar (diameter 1.5 cm, length 50 cm) was positioned 30 cm above the cage floor. Rats (Adlkofer et al., 1995) . Thus, PMP22-dependent neuropaged 1 month, 2.5 months, and 6 months were placed on the middle athies may present a continuum of disease expression.
of the bar. The time (in seconds) that animals remained on the bar
The rodent models hold the promise that the underlying was monitored. In a series of 6 trials per animal, a maximum of 5 cellular defect can be identified with techniques that are min per trial was allowed. The rotarod-test utilized a motor-driven not applicable to patient biopsy material. In fact, as metal roller (10 cm diameter, 10 cm wide) flanked by two larger DNA-based tests for CMT become routine, less human plates. Rats were placed on the roller and (after 30 s at rest) the roller was started at 1 round per min (rpm). In 60 s intervals, the biopsy material is available for research that may be rotating speed was successively increased to 2, 4, 8, 12, 16, and overcome with a suitable animal model. 20 rpm. In a series of 6 trials per animal, the time (in seconds) in Sciatic nerves from newborn rats are the preferred which the rats remained on the roller was measured. Footprints starting material for the generation of purified Schwann were taken with waterproof black ink on watercolor paper. Ink was cell cultures that should hold the key to understanding applied to the hindpaws. Rats aged 2.5 months (5 transgenics, 5 the cellular defect caused by PMP22 overexpression. wild types) were analyzed when walking forward in a 12 cm wide alley.
We have utilized the CMT rat to test the suggestion that PMP22 overexpression acts via a dysregulation of of antidromically activated motoneurons (F-waves) were also re-
In conclusion, we anticipate that the PMP22-transcorded. The distance between the two sites of stimulation was meagenic rat and the corresponding Schwann cell culture sured alongside the skin surface with the leg fully extended, and system will provide a bona fide research tool for the the conduction velocity calculated automatically. For sensory meadissection of the CMT1A disease mechanism, and hopesurements, the nerve action potential was recorded from the digits fully, for the development of therapeutic strategies. through a pair of surface electrodes.
Histology Experimental Procedures
Rats aged 5 weeks, 2.5 months, and 6 months were perfused through the left ventricle with saline followed by 5% glutaraldehyde/ Molecular Cloning 4% paraformaldehyde in cacodylate buffer (pH 7.2). Samples were The PMP22 gene was isolated from a mouse SV129 cosmid library removed from the optic nerve, cervical, thoracic, and lumbar regions (provided by Z. Dembic), using a 2 kb BamHI-EcoRI fragment (5Ј of the spinal cord, lumbar and brachial spinal nerve roots, cranial probe in Figure 1A) . A 43 kb genomic insert was released by NruI nerves V and XII, and the following peripheral nerves: sciatic, tibial, digestion, purified by agarose gel electrophoresis, and isolated usvagus, and brachial plexus. Blocks were osmicated and processed ing the Biotrap electroeluter (Schleicher and Schü ll, Datteln, Gerroutinely for resin embedding. Samples of sciatic nerves were also many). DNA was desalted and equilibrated in the injection buffer (5 postfixed in Dalton's chrome-osmium and processed for teasing in mM Tris-HCl [pH 7.5], 5 mM NaCl, 0.1 mM EDTA) using a Centricon Araldite resin. Sections (1 m) were stained with methylenblue/azure 30 concentrator (Amicon Incorporated, Beverly, MA), and was ster-II for light microscopy and 600A grids double stained for electron ile-filtered with a prewashed 0.22 m filtration unit (Millipore, Bedmicroscopy. ford, MA). DNA was diluted to 2 ng/l and used for the generation of transgenic rats.
RNA Analysis
Total RNA was isolated from sciatic nerves, lung, brain, liver, and Transgenic Rats Pronuclear microinjection of fertilized rat eggs (Sprague-Dawley) kidney of 4 week-old, 2.5 month-old, and 6 month-old rats using the guanidine thiocyanate/water-saturated phenol procedure was carried out as described by Ganten et al. (1991) . Tail biopsy DNA (10 g) was digested with BamHI, size separated on 0.8% (Chomczynski and Sacchi, 1987) . For RT-PCR analysis, cDNA was synthesized from total RNA using random hexamer primers and agarose gels, and Southern blots were hybridized with a mouse PMP22 genomic probe derived from the 5Ј end of the injected frag-MLV reverse transcriptase (Gibco) and quantified by incorporating trace label amounts of ( 32 P)-dCTP. To amplify endogenous plus ment. The founder male was mated to Sprague-Dawley females to establish a transgenic line. Routine genotype analysis was pertransgene-derived PMP22 cDNA, primers were used corresponding to exon 3 (5Ј-CTGTACCACATCCGCCTTGG-3Ј) and exon 5 (5Ј-TCA formed with species-specific primers C (5Ј-GACAAACCCCAGAC AGTTG-3Ј) and D (5Ј-CCAGAAAGCC-AGGGAACTC-3Ј), as indicated ACACGAGGCTGACGGTC-3Ј) of the mouse PMP22 gene. To distinguish endogenousrat mRNA fromtransgene-derived mRNA,RT-PCR in Figure 1A (mouse-specific nucleotides are underlined). PCR was carried out in a 50 l volume under standard conditions, resulting products were digested with PstI (yielding mouse-specific fragments of 66 bp and 570 bp) or NotI (yielding rat-specific fragments of 156 bp in a 501 bp transgene-specific product. Homozygous transgenic rats were obtained by brother-sister matings and identified by pheand 480 bp), and size-separated on 5% polyacrylamide gels. All quantitative PCR amplificationswere carried outwith 4ng cDNA, notype and the 2-fold higher hybridization signal in Southern blots,
